DE69918072D1 - P53-regulierte gene - Google Patents

P53-regulierte gene

Info

Publication number
DE69918072D1
DE69918072D1 DE69918072T DE69918072T DE69918072D1 DE 69918072 D1 DE69918072 D1 DE 69918072D1 DE 69918072 T DE69918072 T DE 69918072T DE 69918072 T DE69918072 T DE 69918072T DE 69918072 D1 DE69918072 D1 DE 69918072D1
Authority
DE
Germany
Prior art keywords
genes
expression
regulated
bypassed
defects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918072T
Other languages
English (en)
Other versions
DE69918072T2 (de
Inventor
J Levine
E Murphy
H Mack
C Gish
Yat Tom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymetrix Inc
Princeton University
Original Assignee
Affymetrix Inc
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymetrix Inc, Princeton University filed Critical Affymetrix Inc
Application granted granted Critical
Publication of DE69918072D1 publication Critical patent/DE69918072D1/de
Publication of DE69918072T2 publication Critical patent/DE69918072T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69918072T 1998-03-27 1999-03-26 P53-regulierte gene Expired - Lifetime DE69918072T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/049,025 US6020135A (en) 1998-03-27 1998-03-27 P53-regulated genes
US49025 1998-03-27
PCT/US1999/006656 WO1999050456A1 (en) 1998-03-27 1999-03-26 P53-regulated genes

Publications (2)

Publication Number Publication Date
DE69918072D1 true DE69918072D1 (de) 2004-07-22
DE69918072T2 DE69918072T2 (de) 2005-07-07

Family

ID=21957674

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918072T Expired - Lifetime DE69918072T2 (de) 1998-03-27 1999-03-26 P53-regulierte gene

Country Status (8)

Country Link
US (3) US6020135A (de)
EP (1) EP1064404B1 (de)
JP (1) JP2002509732A (de)
AT (1) ATE269415T1 (de)
AU (1) AU3208599A (de)
CA (1) CA2324444A1 (de)
DE (1) DE69918072T2 (de)
WO (1) WO1999050456A1 (de)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6355430B1 (en) * 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
JP2004537958A (ja) * 2000-02-22 2004-12-24 オックスフォード バイオメディカ（ユーケイ）リミテッド 差次的発現スクリーニング法
US6884578B2 (en) * 2000-03-31 2005-04-26 Affymetrix, Inc. Genes differentially expressed in secretory versus proliferative endometrium
JP2003533986A (ja) * 2000-05-04 2003-11-18 エイブイアイ バイオファーマ， インコーポレイテッド スプライス領域アンチセンス組成物および方法
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040175770A1 (en) * 2000-06-30 2004-09-09 Nori Matsunami Method of screening for chemotherapeutic treatments for cancer
US7567870B1 (en) 2000-07-31 2009-07-28 Institute For Systems Biology Multiparameter analysis for predictive medicine
DE10037769A1 (de) * 2000-08-03 2002-02-21 Epigenomics Gmbh Diagnose von mit CD24 assoziierten Krankheiten
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US6713257B2 (en) * 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7108969B1 (en) * 2000-09-08 2006-09-19 Affymetrix, Inc. Methods for detecting and diagnosing oral cancer
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
DE10048633A1 (de) * 2000-09-25 2002-04-18 Schering Ag Methode zur in vitro Diagnostik von Endometriose
US6743897B1 (en) 2000-11-27 2004-06-01 Cytokinetics, Inc. Aspergillus fumigatus profilin
US6403372B1 (en) 2000-11-27 2002-06-11 Cytokinetics, Inc. Aspergillus fumigatus profilin
CA2449647A1 (en) * 2001-06-05 2002-12-12 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
DE60237917D1 (de) * 2001-06-05 2010-11-18 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
US6696256B1 (en) 2001-06-08 2004-02-24 Pandmics, Inc. Method, array and kit for detecting activated transcription factors by hybridization array
US20040214166A1 (en) * 2001-06-08 2004-10-28 Xianqiang Li Method for identifying a disease state based on a detected mixture of activated transcription factors
US6821737B2 (en) 2001-06-08 2004-11-23 Panomics, Inc. Method for screening for drug candidates for modulating transcription factor activity
US7981842B2 (en) 2001-06-08 2011-07-19 Panomics, Inc. Method for detecting transcription factor-protein interactions
US6924113B2 (en) 2001-06-08 2005-08-02 Panomics, Inc. Method and kit for isolating DNA probes that bind to activated transcription factors
US7343247B2 (en) * 2001-07-30 2008-03-11 The Institute For Systems Biology Methods of classifying drug responsiveness using multiparameter analysis
AU2002336410A1 (en) * 2001-08-29 2003-09-09 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
CN1927466A (zh) * 2001-12-19 2007-03-14 阿菲梅特里克斯公司 阵列板和阵列板的构建方法
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
CN1675374A (zh) * 2002-08-19 2005-09-28 阎云 肝脏疾病的治疗
EP1570080A4 (de) * 2002-11-15 2006-03-01 Genomic Health Inc Genexpressionsprofilierung einer egfr-positiven krebserkrankung
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
DE602004017426D1 (de) * 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP2327796A1 (de) 2003-06-10 2011-06-01 The Trustees Of Boston University Nachweismethoden für Lungenerkrankungen
JP4680898B2 (ja) * 2003-06-24 2011-05-11 ジェノミック ヘルス， インコーポレイテッド 癌再発の可能性の予測
EP3330875B1 (de) 2003-07-10 2021-12-01 Genomic Health, Inc. Expressionsprofilalgorithmus und -test zur prognose des wiederauftretens von brustkrebs
SG146682A1 (en) * 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
JP2007509613A (ja) * 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
US20050196782A1 (en) * 2003-12-23 2005-09-08 Kiefer Michael C. Universal amplification of fragmented RNA
EP1564306B1 (de) 2004-02-17 2013-08-07 Affymetrix, Inc. Verfahren zur Fragmentierung und Markierung von DNS
JP4545189B2 (ja) 2004-03-24 2010-09-15 トライパス イメイジング インク 子宮頸部疾患を検出するための方法及び組成物
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
EP1647600A3 (de) 2004-09-17 2006-06-28 Affymetrix, Inc. (A US Entity) Verfahren zur Kennzeichnung von biologischen Proben durch Hinzufügung von Nukleinsäre "bar-code" Markierungen
EP1794593A2 (de) * 2004-09-21 2007-06-13 Matritech, Inc. Verfahren und zusammensetzungen zum nachweis von krebs unter verwendung von komponenten des u2-spleissosompartikels
US20060073511A1 (en) 2004-10-05 2006-04-06 Affymetrix, Inc. Methods for amplifying and analyzing nucleic acids
EP1802978B1 (de) * 2004-10-14 2011-11-23 Genentech, Inc. Cop1-moleküle und verwendungen davon
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
CA2524964A1 (en) 2004-10-29 2006-04-29 Affymetrix, Inc. Automated method of manufacturing polymer arrays
EP1815014B1 (de) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
CA3061785A1 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
WO2006113467A2 (en) 2005-04-14 2006-10-26 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
KR20080011289A (ko) * 2005-05-10 2008-02-01 시너젠즈 바이오사이언스 리미티드 폐기능 및 폐질환을 평가하기 위한 성분 및 평가 방법
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
HRP20130852T1 (en) 2005-05-18 2013-10-25 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2006123955A2 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
US20060281114A1 (en) * 2005-05-19 2006-12-14 Young Robert P Methods and compositions for assessment of pulmonary function and disorders
WO2006123943A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
WO2007014105A2 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for adapting a radiation therapy treatment plan based on a biological model
CA2616272A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of detecting a breathing phase of a patient receiving radiation therapy
CN101268467B (zh) 2005-07-22 2012-07-18 断层放疗公司 用于评估治疗计划的实施中的质量保证标准的方法和系统
US7839972B2 (en) * 2005-07-22 2010-11-23 Tomotherapy Incorporated System and method of evaluating dose delivered by a radiation therapy system
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
US7639853B2 (en) 2005-07-22 2009-12-29 Tomotherapy Incorporated Method of and system for predicting dose delivery
CA2616301A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating delivered dose
US8767917B2 (en) * 2005-07-22 2014-07-01 Tomotherapy Incorpoated System and method of delivering radiation therapy to a moving region of interest
CN101500648B (zh) 2005-07-22 2012-07-04 断层放疗公司 利用剂量体积直方图生成轮廓结构的系统和方法
KR20080044252A (ko) * 2005-07-22 2008-05-20 토모테라피 인코포레이티드 방사선 요법 치료 계획에 관한 데이터의 처리 방법 및시스템
US7567694B2 (en) * 2005-07-22 2009-07-28 Tomotherapy Incorporated Method of placing constraints on a deformation map and system for implementing same
KR20080044247A (ko) * 2005-07-22 2008-05-20 토모테라피 인코포레이티드 의료 기기의 동작을 모니터링하는 시스템 및 방법
CN101267767A (zh) 2005-07-23 2008-09-17 断层放疗公司 使用机架和治疗床的协同运动的放射疗法成像和实施
JP2009506778A (ja) * 2005-09-02 2009-02-19 ザ・ユニバーシティ・オブ・トレド 生物学的状態の診断および／または治療に有用なバイオマーカを同定する方法および組成物
EP1941057A4 (de) * 2005-10-07 2009-11-11 Baylor Res Inst Diagnose des systemischen ausbruchs juveniler idiopathischer arthritis über blutleukozyten-mikroarrayanalyse
US7846664B2 (en) * 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
US7634363B2 (en) 2005-12-07 2009-12-15 Affymetrix, Inc. Methods for high throughput genotyping
WO2007069882A1 (en) * 2005-12-13 2007-06-21 Erasmus University Medical Center Rotterdam Genetic brain tumor markers
BRPI0707249A2 (pt) 2006-01-27 2011-04-26 Tripath Imaging, Inc métodos para identificar pacientes com maior probabilidade de terem cáncer de ovário e composições para os mesmo
JP2009529329A (ja) 2006-03-09 2009-08-20 トラスティーズ オブ ボストン ユニバーシティ 鼻腔上皮細胞の遺伝子発現プロファイルを用いた、肺疾患のための診断および予後診断の方法
EP2389948A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008024114A1 (en) * 2006-08-24 2008-02-28 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia
WO2008048986A2 (en) * 2006-10-17 2008-04-24 Children's Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
JP2010508826A (ja) 2006-11-03 2010-03-25 ベイラー リサーチ インスティテュート 血中白血球マイクロアレイ分析を介した、転移性メラノーマの診断及び免疫抑制インディケーターのモニタリング
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
JP5683964B2 (ja) 2008-03-11 2015-03-11 ナショナル キャンサー センター Ｓｎｐアレイを用いた染色体、遺伝子または特定ヌクレオチド配列のコピー数測定方法
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
JP5740302B2 (ja) 2008-05-30 2015-06-24 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール
AU2010226726B8 (en) 2009-03-16 2014-08-14 Pangu Biopharma Limited Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
EP2414513B1 (de) 2009-03-31 2015-10-28 Atyr Pharma, Inc. Zusammensetzungen und verfahren mit aspartyl-trna-synthetasen mit nichtkanonischen biologischen aktivitäten
EP2488873B1 (de) 2009-10-16 2015-08-05 Novartis AG Biomarker für pharmakodynamische tumorreaktionen
CN102640001A (zh) 2009-11-05 2012-08-15 诺瓦提斯公司 预测纤维化进展的生物标记物
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
WO2011079280A2 (en) 2009-12-23 2011-06-30 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
IN2012DN06588A (de) 2010-02-10 2015-10-23 Novartis Ag
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797271C (en) 2010-04-28 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
EP2566495B1 (de) 2010-05-03 2017-03-01 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-alpha-trna-synthetasen
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
EP2568996B1 (de) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
CA3113343C (en) 2010-06-03 2024-10-08 Pharmacyclics Llc USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA
US20120009177A1 (en) 2010-06-07 2012-01-12 Roche Molecular Systems, Inc. Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN112501118A (zh) 2010-08-12 2021-03-16 菲特治疗公司 改进的造血干细胞和祖细胞疗法
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
JP6163104B2 (ja) 2010-11-15 2017-07-12 アクセラレイテッド・バイオサイエンシズ・コーポレーション ヒト・トロホブラスト幹細胞からの神経幹細胞の生成
CA2819378A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
RU2564122C2 (ru) 2011-02-24 2015-09-27 Хилл'С Пет Ньютришн, Инк. Способ и набор для диагностики гломерулонефрита у кошки
JP2014508165A (ja) 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
JP6105491B2 (ja) 2011-03-02 2017-03-29 バーグ エルエルシー 照合性細胞ベースのアッセイ及びその使用
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
WO2012129100A1 (en) 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
CN103597097B (zh) 2011-06-15 2016-08-17 希尔氏宠物营养品公司 用于诊断和监测猫科动物的甲状腺功能亢进的组合物和方法
US20140017174A1 (en) 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
AU2012355775B2 (en) 2011-12-19 2015-10-08 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating hyperthyroidism in companion animals
IN2014MN01642A (de) 2012-02-16 2015-07-03 Atyr Pharma Inc
ES2663234T3 (es) 2012-02-27 2018-04-11 Cellular Research, Inc Composiciones y kits para recuento molecular
ES2776673T3 (es) 2012-02-27 2020-07-31 Univ North Carolina Chapel Hill Métodos y usos para etiquetas moleculares
US10061887B2 (en) 2012-04-02 2018-08-28 Berg Llc Interrogatory cell-based assays and uses thereof
WO2013152307A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Gene expression panel for breast cancer prognosis
WO2013177245A2 (en) 2012-05-22 2013-11-28 Nanostring Technologies, Inc. Nano46 genes and methods to predict breast cancer outcome
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
CA2892822C (en) 2012-11-27 2023-08-08 Pontificia Universidad Catolica De Chile Compositions and methods for diagnosing thyroid tumors
CA2891542C (en) 2012-11-30 2021-12-14 Accelerated Biosciences Corp. Pancreatic progenitor cells expressing betatrophin and insulin
EP2946214A1 (de) 2013-01-21 2015-11-25 AbbVie Inc. Anti-tnf- und anti-il17-kombinationstherapie-biomarker für entzündungskrankheiten
CN105027227B (zh) 2013-02-26 2017-09-08 安科锐公司 电磁致动的多叶准直器
AU2014223824B2 (en) 2013-02-28 2020-02-27 Albert Einstein College Of Medicine, Inc. Tuberculosis biomarkers and uses thereof
JP2016537010A (ja) 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
AU2014329547B2 (en) 2013-10-02 2019-05-16 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for purification
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
DK3110973T3 (da) 2014-02-27 2019-05-13 Univ Leuven Kath Oxidativt stress og kardiovaskulære sygdomshændelser
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
US10829819B2 (en) 2014-05-30 2020-11-10 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3210144B1 (de) 2014-10-24 2020-10-21 Koninklijke Philips N.V. Medizinische prognose und vorhersage der behandlungsreaktion mithilfe der aktivitäten mehrerer zellsignalisierungspfade
ES2833543T3 (es) 2014-10-24 2021-06-15 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de TGF usando modelos matemáticos de la expresión de genes diana
WO2016062892A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
EP3224347A4 (de) 2014-11-26 2018-08-15 Accelerated BioSciences Corp. Induzierte hepatozyten und verwendungen davon
ES2748005T3 (es) 2014-12-12 2020-03-12 Medivation Prostate Therapeutics Llc Método para predecir la respuesta a agentes terapéuticos de cáncer de mama y método de tratamiento de cáncer de mama
DK3234112T3 (da) 2014-12-19 2020-03-02 Univ Brussel Vrije In vitro-modning af et pattedyre-cumulus-oocytkompleks
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
JP6923509B2 (ja) 2015-07-28 2021-08-18 オトノミ—，インク． 切断型のｔｒｋｂおよびｔｒｋｃのアンタゴニストを使用する処置
US11450409B2 (en) 2015-08-14 2022-09-20 Innosign B.V. Determination of NFkB pathway activity using unique combination of target genes
EP3901279B1 (de) 2015-10-18 2023-05-17 Affymetrix, Inc. Multiallele genotypisierung von einzelnukleotidpolymorphismen und indels
KR20170076480A (ko) 2015-12-24 2017-07-04 삼성전자주식회사 Pint 유전자의 발현 저해제 또는 pint의 활성 저해제를 포함하는 조성물 및 그의 용도
CN116509869A (zh) 2016-04-04 2023-08-01 希诺皮亚生物科学公司 使用曲匹地尔治疗锥体外系综合征
CN109790583B (zh) 2016-05-17 2023-08-25 基因中心治疗公司 对肺腺癌亚型分型的方法
WO2017201164A1 (en) 2016-05-17 2017-11-23 Genecentric Diagnostics, Inc. Methods for subtyping of lung squamous cell carcinoma
EP3260552A1 (de) 2016-06-20 2017-12-27 Istituto Europeo di Oncologia (IEO) Verfahren und kits mit gensignaturen zur stratifizierung von brustkrebspatienten
WO2018013883A1 (en) 2016-07-14 2018-01-18 Caprion Proteomics Inc. Biomarkers of latent tuberculosis infection
WO2018015375A1 (en) 2016-07-20 2018-01-25 Westfälische Wilhelms-Universität Münster Complex-specific standardization of immunological methods for the quantification of s100a12
EP3655418A4 (de) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Verfahren zur behandlung von glioblastom
WO2019018764A1 (en) 2017-07-21 2019-01-24 Genecentric Therapeutics, Inc. METHODS OF DETERMINING RESPONSE TO PARP INHIBITORS
EP3665199A4 (de) 2017-08-07 2021-08-11 Genecentric Therapeutics, Inc. Verfahren zur subtypisierung von plattenepithelkarzinomen an kopf und hals
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
EP3461916A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der zellulären jak-stat3-signalisierungspfadaktivität mittels mathematischer modellierung der zielgenexpression
EP3461915A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären jak-stat1/2-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
EP3502279A1 (de) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären mapk-ap 1-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
WO2019160914A1 (en) 2018-02-13 2019-08-22 Genecentric Therapeutics, Inc. Methods for subtyping of bladder cancer
ES2960914T3 (es) 2018-03-16 2024-03-07 Gopath Laboratories Llc Métodos para la detección personalizada de la reaparición del cáncer o de la metástasis y/o evaluación de la respuesta al tratamiento
CN121041959A (zh) 2018-05-29 2025-12-02 生捷科技控股公司 在基材提高光化学反应的效率
WO2020049106A1 (en) 2018-09-05 2020-03-12 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft A method for engineering synthetic cis-regulatory dna
US20210388449A1 (en) 2018-10-09 2021-12-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
WO2020104482A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma
EA202191741A1 (ru) 2018-12-20 2021-10-25 Ауранса Инк. Аналоги пентамидина и их применение
EP3908668A4 (de) 2019-01-11 2022-11-09 University of Virginia Patent Foundation Zusammensetzungen und verfahren zur vorhersage der abnahme der lungenfunktion bei idiopathischer lungenfibrose
WO2021188611A1 (en) 2020-03-18 2021-09-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
CN115916180A (zh) 2020-03-26 2023-04-04 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物
EP3907301A1 (de) 2020-05-08 2021-11-10 Istituto Europeo di Oncologia S.r.l. Methoden und kits zur bestimmung des risikos eines erneuten auftretens von brustkrebs
US20250305055A1 (en) 2021-12-22 2025-10-02 Cornell University Prognostic/predictive breast cancer signature

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810400D0 (en) * 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
DE69032864T3 (de) * 1989-03-29 2013-01-31 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
US5936079A (en) * 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
WO1993021529A1 (en) * 1992-04-14 1993-10-28 Duke University Method of detecting tumors containing complexes of p53 and hsp70
AU5605994A (en) * 1992-11-12 1994-06-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for determining the presence of functional p53 in mammalian cells
ATE199568T1 (de) * 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
AU1211895A (en) * 1993-11-22 1995-06-13 Onyx Pharmaceuticals P53-binding polypeptides and polynucleotides encoding same
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5667987A (en) * 1994-07-12 1997-09-16 Bristol-Myers Squibb Company P53 response genes
US5702908A (en) * 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
CA2232000A1 (en) * 1995-09-14 1997-03-20 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
DE69628936T2 (de) * 1995-09-18 2004-05-27 Cancer Research Technology Ltd. Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen
AU8382998A (en) * 1997-07-02 1999-01-25 Genzyme Corporation P53 influenced gene expression
US6479285B1 (en) * 1997-07-02 2002-11-12 Board Of Regents, The University Of Texas System p53 as a regulator of cell differentiation
DE19735221C1 (de) * 1997-08-14 1999-05-06 Wolfgang Willi Prof Dr Deppert Beeinflussung der Bindung von p53 an Zielgene
WO1999014356A2 (en) * 1997-09-17 1999-03-25 The Johns Hopkins University P53-induced apoptosis
WO1999016790A1 (en) * 1997-09-26 1999-04-08 University Technologies International, Inc. Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
US6297366B1 (en) * 1998-01-14 2001-10-02 Board Of Trustees Of The University Of Illinois ING-encoded p33ING1 protein as a mediator of p53 signaling pathway in mammalian cells
DE19847779C1 (de) * 1998-10-16 2000-02-03 Deutsches Krebsforsch p53-Bindungsregionen
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response

Also Published As

Publication number Publication date
DE69918072T2 (de) 2005-07-07
EP1064404A1 (de) 2001-01-03
HK1038595A1 (en) 2002-03-22
ATE269415T1 (de) 2004-07-15
JP2002509732A (ja) 2002-04-02
US6020135A (en) 2000-02-01
US20010039013A1 (en) 2001-11-08
CA2324444A1 (en) 1999-10-07
AU3208599A (en) 1999-10-18
EP1064404B1 (de) 2004-06-16
US6171798B1 (en) 2001-01-09
WO1999050456A1 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
DE69918072D1 (de) P53-regulierte gene
Imagawa et al. Association of reduced type IX collagen gene expression in human osteoarthritic chondrocytes with epigenetic silencing by DNA hypermethylation
Kalantry et al. The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation
Esposito et al. HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs
EP0804548A4 (de) Ptc gene und ihre verwendung
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
DE60039072D1 (de) Verfahren zum screenen von mehrfach transformierteon von fluoreszenzproteinen
ATE257177T1 (de) Adeno-assoziierte virale (avv) liposomen und damit zusammenhängende verfahren
Ogawa et al. Stimulation of transcription accompanying relaxation of chromatin structure in cells overexpressing high mobility group 1 protein
IT8024536A0 (it) Dispersioni stabili di colofonia rinforzata.
Woodstock et al. p63 and p53: collaborative partners or dueling rivals?
TR200003377T2 (tr) Estrojenler ile bütünleşik 2-fenil-1-[4-(2-aminoetoksi)benzil]-indol
AU520928B2 (en) Compensating the magnetic field induced by the adjacent line in series of high intensity electrolysis cells
ATE295888T1 (de) Genfallen-konstrukt zur identifizierung und isolierung von genen
DE60228609D1 (de) Identifizierung und charakterisierung von genen
Nakamura et al. The combination of ubiquitous transcription factors AP‐1 and Sp1 directs keratinocyte‐specific and differentiation‐specific gene expression in vitro
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
HU9503363D0 (en) Process for screening substances having a modulating effect on an interleukine-5-receptor-dependent cellular signal transmission path
Aiken The analysis of the gravity anomalies of Arizona
BR9708256A (pt) Processo para identificar genes com expresão específica ao síto ou de síto preferido em células de marcacção específicas presentes em um ambiente de células diferente ou não daquele de sua origem e uso do mesmo
DE69032716D1 (de) Piperazin-Piperidin-Verbindungen für Verwendung als Stabilisatoren für organische Materialien
ATE236247T1 (de) Methoden zum aufspüren von anti- östrogenverbindungen
EP1814994A4 (de) Vorrichtung und system mit trockenen kontrollgen-verstummungszusammensetzungen
DK0898708T3 (da) Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays

Legal Events

Date Code Title Description
8364 No opposition during term of opposition